Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Clinical Data-Matched Patient Organoids Customize Drug-Resistant TNBC Treatment

6 August 2026 · By · Wire by Fusion42

Published

6 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at insideprecisionmedicine.com →

◆ Verified

Fusion42 · 30 August 2026 · Fusion42 review

Researchers at UCSF developed a framework that uses clinically validated biomarkers from the I-SPY2 breast cancer trial to identify drug-resistant triple-negative breast cancer (TNBC) subtypes in patient-derived organoids and screen for effective treatments, revealing new therapy candidates like navitoclax and ganetespib.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now use clinical trial data to select organoids that predict patient drug response precisely, turning lab models into real trial extensions. This opens a faster path to drug discovery tailored to resistant breast cancers and beyond.

◆ Coverage

1 source · 6 Aug 2026

◆ Related on Wire

◆ Topics

Biotechprecision-oncologydrug-resistancepatient-organoidstnbcbiomarkersdrug-discovery